Abstract:
A supporter includes a body section having a back-contact section, a first auxiliary band section of which one end is fixed to the top end of a left side of the back-contact section and the other end is fixed to the bottom end of a right side of the back-contact section, a second auxiliary band section forming a pair with the first auxiliary band section, a first ring arranged to slide between the one end and the other end of the first auxiliary band section, a second ring forming a pair with the first ring, a first adjustment band section of which one end is fixed to loops on a right end side of the body section and the other end can be fastened to loops on the right end side of the body section, and a second adjustment band section forming a pair with the first adjustment band section.
Abstract:
Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.
Abstract:
The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.
Abstract:
The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARγ activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.
Abstract translation:本发明提供:下述通式(I)表示的化合物,既具有血管紧张素II受体拮抗作用又具有PPARγ活化作用,可用作高血压,心脏病,动脉硬化等的预防和/或治疗剂, 2型糖尿病等; 和含有该化合物的药物组合物。 通式(I)(式中,环A表示吡啶环;环B表示四唑环或恶二唑-5(4H) - 酮环; X表示C-R5或氮原子; R1表示烷基 ; R 2表示烷基或环烷基; R 3,R 4和R 5各自独立地表示氢原子,卤素原子,烷基,烷氧基等。
Abstract:
When assessing the start time of the limulus reaction between biogenous biologically active substances and LAL and using the reaction start time to determine the concentration of the biogenous biologically active substances, in order to exclude the influence of progressive changes which occur regardless of the conditions of the limulus reaction, the strength of transmitted light or scattered light in the liquid mixture of the measurement sample and LAL is detected, the variation (delta) in the transmittance or number of gel particles is acquired at set intervals, and the time when the variation (delta) crosses a threshold value is taken as the reaction start time. Furthermore, the time intervals when acquiring the abovementioned delta are not uniform, and either change over time from the start of measurement as defined by a time function, or multiple sequences with differing time intervals are prepared in advance.
Abstract:
[Problem] To increase, compared to conventional devices, the range of motion of the light emitter (fixation lamp) in an external fixation lamp for an ophthalmological instrument and allow movement of the light emitter to arbitrary positions.[Solution] The fixation lamp (1) has a first arm (A1), which supports a light emitter (2) and is supported by a second arm (A2) via a first joint (C1), and is configured so that the first arm (A1) is able to revolve around at least two axes of revolution (E1, E2) by means of the first joint (C1) and said axes of rotation (E1, E2) are not disposed on the same line. Thereby, the range in which the light emitter (2) can be moved can be increased compared to conventional devices and the light emitter can be moved to an arbitrary position in an arbitrary direction.
Abstract:
A telephoto lens unit (1) having a lens barrel that supports a telephoto lens and capable of being mounted on and dismounted from a camera body (16) comprises a front lens barrel section (11) that supports the telephoto lens with the subject side defined as the front, and a rear lens barrel section (13) that can be mounted on and dismounted from the front lens barrel section. The distance from the image-most surface of the telephoto lens to the image formation plane of the telephoto lens is kept sufficiently long. Converter lens units (12, 14) for elongating or shortening the focal distance are mounted on the front lens barrel section (11) instead of the rear lens barrel section (13) to provide interchangeable telephoto lenses for a camera having different focal lengths. Also, an erecting prism unit (15) and an eyepiece unit (17) can be connected instead of the rear lens barrel section to enable the telephoto lens to function as a terrestrial telescope.
Abstract:
An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.
Abstract:
Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.
Abstract:
Disclosed is a technique which simplifies the adjustment of a reagent which makes the proteins contained in limulus amoebocyte lysate (LAL) attach to the surface of microparticles dispersed in a prepared drug solution, and which can improve the accuracy of the detection of a predetermined physiologically active substance or the measurement of the concentration thereof. A reagent is prepared which adsorbs the proteins contained in LAL to beads dispersed in a drug solution prepared in advance. By reacting a sample containing an endotoxin with the reagent, groups of the beads associate and rapidly form large aggregates, and measurement of the endotoxin is carried out by the detecting the formation of the aggregates. The beads are formed from an inorganic material such as alumina, kaolin, or manganese oxide.